Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease

Non-Motor Working Group of the Parkinson Study Group (PSG)

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of solifenacin succinate in Parkinson's disease (PD) patients suffering from overactive bladder (OAB). Background: Urinary dysfunction is a commonly encountered non-motor feature in PD that significantly impacts patient quality of life. Design/methods: This was a double-blind, randomized, placebo-controlled, 3-site study with an open label extension phase to determine the efficacy of solifenacin succinate in idiopathic PD patients with OAB. Patients were randomized to receive solifenacin succinate 5-10mg daily or placebo for 12 weeks followed by an 8-week open label extension. The primary outcome measure was the change in the mean number of micturitions per 24h period. Secondary outcome measures included the change in the mean number of urinary incontinence episodes and the mean number of nocturia episodes. Results: Twenty-three patients were randomized in the study. There was no significant improvement in the primary outcome measure in the double-blind phase, but there was an improvement in the number of micturitions per 24h period in the solifenacin succinate group compared to placebo at a mean dose of 6mg/day (p=0.01). In the open label phase, the mean number of urinary incontinence episodes per 24h period decreased (p=0.03), as did the number of nocturia episodes per 24h period (p=0.01). Adverse events included constipation and xerostomia, which resolved after treatment was discontinued. Conclusions: In this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms.

Original languageEnglish (US)
Pages (from-to)514-520
Number of pages7
JournalParkinsonism and Related Disorders
Volume21
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Overactive Urinary Bladder
Parkinson Disease
Randomized Controlled Trials
Urinary Incontinence
Nocturia
Urination
Placebos
Outcome Assessment (Health Care)
Xerostomia
Constipation
Quality of Life
Solifenacin Succinate
Therapeutics

Keywords

  • Non-motor symptoms
  • Overactive bladder
  • Parkinson's disease
  • Solifenacin succinate
  • Urinary incontinence

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. / Non-Motor Working Group of the Parkinson Study Group (PSG).

In: Parkinsonism and Related Disorders, Vol. 21, No. 5, 01.05.2015, p. 514-520.

Research output: Contribution to journalArticle

Non-Motor Working Group of the Parkinson Study Group (PSG). / Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. In: Parkinsonism and Related Disorders. 2015 ; Vol. 21, No. 5. pp. 514-520.
@article{c40c729770a748d3ba9aae7b694344c4,
title = "Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease",
abstract = "Objective: To evaluate the efficacy of solifenacin succinate in Parkinson's disease (PD) patients suffering from overactive bladder (OAB). Background: Urinary dysfunction is a commonly encountered non-motor feature in PD that significantly impacts patient quality of life. Design/methods: This was a double-blind, randomized, placebo-controlled, 3-site study with an open label extension phase to determine the efficacy of solifenacin succinate in idiopathic PD patients with OAB. Patients were randomized to receive solifenacin succinate 5-10mg daily or placebo for 12 weeks followed by an 8-week open label extension. The primary outcome measure was the change in the mean number of micturitions per 24h period. Secondary outcome measures included the change in the mean number of urinary incontinence episodes and the mean number of nocturia episodes. Results: Twenty-three patients were randomized in the study. There was no significant improvement in the primary outcome measure in the double-blind phase, but there was an improvement in the number of micturitions per 24h period in the solifenacin succinate group compared to placebo at a mean dose of 6mg/day (p=0.01). In the open label phase, the mean number of urinary incontinence episodes per 24h period decreased (p=0.03), as did the number of nocturia episodes per 24h period (p=0.01). Adverse events included constipation and xerostomia, which resolved after treatment was discontinued. Conclusions: In this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms.",
keywords = "Non-motor symptoms, Overactive bladder, Parkinson's disease, Solifenacin succinate, Urinary incontinence",
author = "{Non-Motor Working Group of the Parkinson Study Group (PSG)} and Zesiewicz, {Theresa A.} and Marian Evatt and Vaughan, {Camille P.} and Israt Jahan and Carlos Singer and Raul Ordorica and Salemi, {Jason L.} and Shaw, {Jessica D.} and Sullivan, {Kelly L.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.parkreldis.2015.02.025",
language = "English (US)",
volume = "21",
pages = "514--520",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease

AU - Non-Motor Working Group of the Parkinson Study Group (PSG)

AU - Zesiewicz, Theresa A.

AU - Evatt, Marian

AU - Vaughan, Camille P.

AU - Jahan, Israt

AU - Singer, Carlos

AU - Ordorica, Raul

AU - Salemi, Jason L.

AU - Shaw, Jessica D.

AU - Sullivan, Kelly L.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Objective: To evaluate the efficacy of solifenacin succinate in Parkinson's disease (PD) patients suffering from overactive bladder (OAB). Background: Urinary dysfunction is a commonly encountered non-motor feature in PD that significantly impacts patient quality of life. Design/methods: This was a double-blind, randomized, placebo-controlled, 3-site study with an open label extension phase to determine the efficacy of solifenacin succinate in idiopathic PD patients with OAB. Patients were randomized to receive solifenacin succinate 5-10mg daily or placebo for 12 weeks followed by an 8-week open label extension. The primary outcome measure was the change in the mean number of micturitions per 24h period. Secondary outcome measures included the change in the mean number of urinary incontinence episodes and the mean number of nocturia episodes. Results: Twenty-three patients were randomized in the study. There was no significant improvement in the primary outcome measure in the double-blind phase, but there was an improvement in the number of micturitions per 24h period in the solifenacin succinate group compared to placebo at a mean dose of 6mg/day (p=0.01). In the open label phase, the mean number of urinary incontinence episodes per 24h period decreased (p=0.03), as did the number of nocturia episodes per 24h period (p=0.01). Adverse events included constipation and xerostomia, which resolved after treatment was discontinued. Conclusions: In this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms.

AB - Objective: To evaluate the efficacy of solifenacin succinate in Parkinson's disease (PD) patients suffering from overactive bladder (OAB). Background: Urinary dysfunction is a commonly encountered non-motor feature in PD that significantly impacts patient quality of life. Design/methods: This was a double-blind, randomized, placebo-controlled, 3-site study with an open label extension phase to determine the efficacy of solifenacin succinate in idiopathic PD patients with OAB. Patients were randomized to receive solifenacin succinate 5-10mg daily or placebo for 12 weeks followed by an 8-week open label extension. The primary outcome measure was the change in the mean number of micturitions per 24h period. Secondary outcome measures included the change in the mean number of urinary incontinence episodes and the mean number of nocturia episodes. Results: Twenty-three patients were randomized in the study. There was no significant improvement in the primary outcome measure in the double-blind phase, but there was an improvement in the number of micturitions per 24h period in the solifenacin succinate group compared to placebo at a mean dose of 6mg/day (p=0.01). In the open label phase, the mean number of urinary incontinence episodes per 24h period decreased (p=0.03), as did the number of nocturia episodes per 24h period (p=0.01). Adverse events included constipation and xerostomia, which resolved after treatment was discontinued. Conclusions: In this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms.

KW - Non-motor symptoms

KW - Overactive bladder

KW - Parkinson's disease

KW - Solifenacin succinate

KW - Urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=84928588814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928588814&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2015.02.025

DO - 10.1016/j.parkreldis.2015.02.025

M3 - Article

C2 - 25814050

AN - SCOPUS:84928588814

VL - 21

SP - 514

EP - 520

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 5

ER -